Straight answers to the questions people actually ask
Most users begin noticing appetite reduction within the first week, but significant weight loss typically begins after 4–8 weeks of treatment. Clinical trials show continued weight loss over 68 weeks, with average results of 15–20% body weight loss depending on the medication and dose. The early weeks are mostly about tolerating the medication, not seeing the scale move.
Studies show that most people regain a significant portion of lost weight within 12 months of discontinuing GLP-1 medications. This is why these are considered long-term treatments for chronic weight management, similar to how blood pressure or cholesterol medications work. Sustainable habits and ongoing medical support matter for maintaining results, but it is worth going in with realistic expectations about what stopping looks like.
Absolutely, and it is strongly recommended. Aim for 150 minutes of moderate aerobic activity per week plus strength training 2–3 times weekly. Strength training is particularly important to preserve muscle mass during weight loss. Start gradually if you are new to exercise, and listen to your body — especially if you are experiencing nausea or fatigue during titration.
Both contain semaglutide, but Wegovy is specifically FDA-approved for chronic weight management and comes in higher doses (up to 2.4 mg versus Ozempic's 2.0 mg). Ozempic is primarily approved for type 2 diabetes, though it is often prescribed off-label for weight loss — which is a common reason for insurance denials. Wegovy also has approval for adolescents aged 12 and up.
Planning is key. Preview menus in advance, focus on protein and vegetables, eat slowly, and do not hesitate to take leftovers home. Consider eating a smaller portion and prioritising protein. It is also worth deciding in advance what you will say if someone comments on how little you are eating. One special occasion will not derail your progress — consistency over time is what matters.
There are no absolute prohibitions, but many users find high-fat, fried or very rich foods trigger nausea or discomfort. Alcohol may affect you faster and harder than before. Carbonated drinks can worsen bloating. Pay attention to your body's signals and adjust — the list of foods that do not agree with you is personal and tends to change as you adjust to a dose.
For weekly medications, if you miss a dose and it is within 5 days of your scheduled dose, take it as soon as you remember. If more than 5 days have passed, skip the missed dose and take your next dose on your regular schedule. Never take two doses to make up for a missed one. Daily medications such as Victoza and Saxenda have different instructions — check the guidance for your specific product, and contact your healthcare provider if you are unsure.
Coverage varies significantly by insurance plan and indication. For diabetes (Ozempic, Mounjaro), coverage is generally better. For weight management (Wegovy, Zepbound), coverage can be limited and some plans exclude weight-loss drugs entirely. Many plans require prior authorisation, step therapy (trying other options first), or documentation of BMI ≥ 30 (or ≥ 27 with comorbidities). Manufacturer savings programmes may help if insurance denies coverage. Our medication guide goes into this in more detail.
Yes. Wegovy and Zepbound are specifically FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. These are appropriate for non-diabetic patients meeting the criteria, subject to your provider's assessment.
Signs of muscle loss include decreased strength, unusual fatigue and a stalled metabolism. To minimise it: consume adequate protein (our calculator gives you a target), do regular strength training, avoid losing weight too rapidly (consistently more than about 2 lbs per week), and consider body composition testing if available. A healthcare provider or dietitian can help monitor this properly — the bathroom scale cannot tell you what kind of weight you lost.
Plateaus are normal and have several common causes: your body adjusts to a given dose, your energy needs fall as you get lighter, or intake has crept up without you noticing. A stall is not a failure, and it is not automatically a reason to increase your dose — that is a decision for your provider. If a plateau persists for several weeks, it is worth reviewing protein intake, activity and sleep before changing anything about the medication.
There is no universal answer, and it depends on why you were prescribed the medication and how you respond. Current evidence suggests that for many people, stopping leads to substantial regain, which is why these are framed as long-term treatments rather than short courses. Some people move to a lower maintenance dose. This is a conversation to have with your provider explicitly, ideally before you start rather than after.
This is worth real caution. Compounded semaglutide and tirzepatide are not FDA-approved products, and the agency has issued warnings about products sold through some online channels, including reports of dosing errors and of salt forms that differ from the approved ingredient. If you are considering a non-standard source because of cost, raise it with your provider or pharmacist first — and check the FDA's current guidance rather than relying on the seller's claims.
Contact your healthcare provider promptly for severe or persistent abdominal pain (particularly pain radiating to your back), vomiting you cannot keep on top of, signs of dehydration, symptoms of gallbladder problems such as upper-right abdominal pain or jaundice, or any signs of an allergic reaction. Also call if side effects during titration are severe enough that you are considering stopping — there are usually options between "push through it" and "quit".